Regulation of peanut-specific CD8+ T cells from nonallergic individuals - 09/01/21
Doi : 10.1016/j.jaci.2020.07.032
Wong Yu, MD, PhD a, b, Xiaoying Zhou, MD, PhD a, b, Shu Chen Lyu, MSc a, b, Mark M. Davis, PhD c, d, e, Kari C. Nadeau, MD, PhD a, b 
a Sean N. Parker Center for Allergy and Asthma Research at Stanford University School of Medicine, Stanford University School of Medicine, Stanford, Calif
b Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, Calif
c Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, Calif
d Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, Calif
e Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, Calif
| This work was funded by the National Institutes of Health (grant nos. R01AI140134 and U19AI104209) and the Sean N. Parker Center for Allergy and Asthma at Stanford University. |
|
| Disclosure of potential conflict of interest: K. C. Nadeau received grants from the National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research & Education (FARE), End Allergies Together, Allergenis, and Ukko Pharma; is a grant awardee at NIAID, National Institute of Environmental Health Sciences, National Heart, Lung, and Blood Institute (NHLBI), and the Environmental Protection Agency (EPA); is involved in clinical trials with Regeneron, Genentech, AImmune Therapeutics, DBV Technologies, AnaptysBio, Adare Pharmaceuticals, and Stallergenes Greer; received research sponsorship by Novartis, Sanofi, Astellas, and Nestle; is a Data and Safety Monitoring Board member at Novartis and NHLBI; cofounded Before Brands, Alladapt, ForTra, and Iggenix; is chief intellectual officer at FARE and director of the World Allergy Organization (WAO) Center of Excellence at Stanford; received personal fees from Regeneron, Astrazeneca, ImmuneWorks, and Cour Pharmaceuticals; is consultant and advisory board member at Ukko, Before Brands, Alladapt, IgGenix, Probio, Vedanta, Centecor, Seed, Novartis, NHLBI, EPA, and National Scientific Committee of Immune Tolerance Network and National Institutes of Health programs; and received US patents (patent nos. 62/647,389, 62/119,014, 12/610,940, 12/686,121, 10/064,936, and 62/767,444; application nos. S10-392). The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 147 - N° 1
P. 385 - Gennaio 2021 Ritorno al numero
Articolo precedente
- No cashew allergy in infants introduced to cashew by age 1 year
- Rachel L. Peters, Danny Ye Barret, Victoria X. Soriano, Vicki McWilliam, Adrian J. Lowe, Anne-Louise Ponsonby, Mimi L.K. Tang, Shyamali C. Dharmage, Lyle C. Gurrin, Jennifer J. Koplin, Kirsten P. Perrett
- Timing of exposure to environmental adjuvants is critical to mitigate peanut allergy
- Johanna M. Smeekens, Robert M. Immormino, Michael D. Kulis, Timothy P. Moran
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?